

Amendments to the Specification

Please amend the specification to include the amended Sequence Listing submitted herewith.

Please replace the paragraph at page 7, lines 21-28, with the following amended paragraph:

The peptides listed in Table 1 are reported to be antagonists of the FP receptor that disrupt the interaction between the FP receptor and the associated $G_{\alpha q}$ protein (WO 99/32640 and WO ~~00/17438~~ 00/17348). The amino acids are indicated according to the standard IUPAC single letter convention, and X is cyclohexyl alanine. Lower case letters indicate L-amino acids and capital letters indicate D-amino acids. All of the disclosure in WO 99/32640 and WO ~~00/17438~~ 00/17348 relating to specific peptides as FP receptor antagonists, is hereby incorporated herein by reference.

Please replace the paragraph at page 13, line 14-21, with the following amended paragraph:

Peptides described in WO 01/42281 (Hopital Sainte-Justine) eg: IFTSYLECL (SEQ ID NO:7), IFASYECL (SEQ ID NO:8), IFTSAECL (SEQ ID NO:9), IFTSYEAL (SEQ ID NO:10), ILASYECL (SEQ ID NO:11), IFTSTDCL (SEQ ID NO:12), ~~TSYEAL~~ XTSYEAL (~~with where X is~~ where X is 4-biphenyl alanine) (SEQ ID NO:13), ~~TSYEAL~~ XTSYEAL (~~with where X is~~ is homophenyl alanine) (SEQ ID NO:14) are also described as EP4 receptor antagonists, as are some of the compounds described in WO 00/18744 (Fujisawa Pharm Co Ltd). The 5-thia-prostaglandin E derivatives described in WO 00/03980 (EP 1 097 922) (Ono Pharm Co Ltd) may be EP4 receptor antagonists.